• Polybrene (Hexadimethrine Bromide): Optimizing Viral Transdu

  2026-04-28

  Polybrene (Hexadimethrine Bromide) 10 mg/mL elevates viral gene transduction and lipid-mediated DNA delivery, overcoming barriers in challenging cell lines. APExBIO’s validated formulation enables researchers to streamline workflows, minimize cytotoxicity, and enhance reproducibility in translational and metabolic studies.

• Transmission Dynamics of Carbapenemase Genes in CREC During

  2026-04-27

  This study provides a detailed molecular epidemiology of carbapenem-resistant Enterobacter cloacae (CREC) isolates from eight teaching hospitals in Guangdong Province, China, during the COVID-19 pandemic. By characterizing carbapenemase-encoding genes (CEGs) and their transmission, the research reveals substantial multidrug resistance and the mechanisms driving horizontal gene transfer, informing infection control and resistance surveillance.

• Estradiol Benzoate (SKU B1941): Reliable Solutions for ERα R

  2026-04-27

  This article provides scenario-driven, evidence-based guidance for biomedical researchers and laboratory professionals using Estradiol Benzoate (SKU B1941) in cell viability, proliferation, and hormone receptor binding assays. By addressing real lab challenges and drawing on validated protocols, it demonstrates how Estradiol Benzoate supports reproducible, sensitive, and robust estrogen receptor signaling research workflows.

• Chloroquine Diphosphate in Autophagy and Innate Immunity Res

  2026-04-26

  Explore how Chloroquine Diphosphate functions as both an autophagy modulator and a TLR7/9 inhibitor, with a deep dive into its unique role in bridging cancer and antiviral research. This article offers advanced scientific insights and practical guidance for leveraging Chloroquine Diphosphate in innovative assay design.

• Optimizing ICC & IHC with HyperFluor™ 594 Goat Anti-Rabbit I

  2026-04-25

  Unlock high-sensitivity detection of rabbit antibodies in complex tissue and cell assays with the HyperFluor™ 594 Goat Anti-Rabbit IgG (H+L) Antibody. This APExBIO reagent streamlines multiplexed immunofluorescence, bridging genomic insights with robust imaging and quantification.

• 4μ8C in Translational Cancer Research: Beyond UPR Dissection

  2026-04-24

  Explore how 4μ8C, a selective unfolded protein response inhibitor, is advancing cancer research by enabling precise modulation of ER stress signaling. This article uniquely connects mechanistic insights and metabolic-immune interplay to guide experimental strategy.

• AR Heterogeneity Dictates Prostate Cancer Therapy Response

  2026-04-24

  This study systematically links androgen receptor (AR) expression heterogeneity in prostate cancer to the spectrum of responses to castration and enzalutamide therapy. The findings provide a mechanistic rationale for stratifying castration-resistant prostate cancer (CRPC) by AR status and highlight BCL-2 as a combinatorial target, informing future therapeutic approaches.

• Genotyping Kit for Target Alleles: Rapid Workflows and Solut

  2026-04-23

  Accelerate PCR-based genotyping across insects, tissues, fishes, and cells with APExBIO’s streamlined single-tube kit. Discover actionable workflow strategies, troubleshooting insights, and translational research applications that bridge bench protocols and real-world genetic analysis.

• PDK4-IN-1 Hydrochloride: Unveiling Metabolic Pathway Precisi

  2026-04-23

  Explore the advanced utility of PDK4-IN-1 hydrochloride as a selective pyruvate dehydrogenase kinase 4 inhibitor. This article delivers in-depth scientific insights into its mechanism, protocol parameters, and unique advantages for mitochondrial energy metabolism studies.

• Scenario-Driven Workflows with Anlotinib Hydrochloride (SKU

  2026-04-22

  This authoritative guide explores how Anlotinib hydrochloride (SKU C8688) from APExBIO empowers biomedical researchers to overcome common laboratory challenges in cell viability, angiogenesis, and cytotoxicity assays. Drawing on peer-reviewed evidence and real-world protocol scenarios, we detail best practices for maximizing assay reproducibility, data integrity, and workflow safety using this reference-grade multi-target tyrosine kinase inhibitor.

• Amikacin (BAY416651): Applied Workflows in Resistance Resear

  2026-04-22

  Amikacin (BAY416651) is pivotal for dissecting antibiotic resistance in Enterobacter cloacae and Klebsiella pneumoniae, offering robust activity even against most aminoglycoside-modifying enzyme-resistant strains. This guide translates the latest research and protocol enhancements into actionable workflows, ensuring reproducibility and data integrity for advanced resistance studies.

• Saquinavir: Optimizing HIV Protease Inhibitor Workflows

  2026-04-21

  Saquinavir empowers researchers to model HIV protease inhibition and drug permeability with advanced biomimetic assays. This article translates cutting-edge findings into actionable workflows, highlighting troubleshooting strategies and protocol refinements for both HIV and cancer research.

• CA-074 Me in Necroptosis: Advancing Cathepsin B Inhibition R

  2026-04-21

  Explore how CA-074 Me, a potent cathepsin B inhibitor, is transforming necroptosis and lysosomal membrane permeabilization research. Delve into its unique mechanism, protocol insights, and the latest scientific breakthroughs that set this reagent apart.

• SU6656 Src Inhibitor: Transforming Platelet and Cancer Resea

  2026-04-20

  This thought-leadership article explores how SU6656, a selective Src tyrosine kinases inhibitor from APExBIO, is redefining experimental strategies in both ex vivo platelet production from human iPSCs and the enhancement of antiangiogenic effects in cancer radiotherapy. By integrating new mechanistic insights and strategic protocol guidance, the piece offers a roadmap for translational researchers aiming for reproducibility, scalability, and clinical impact. Evidence-labeled data and protocol parameters are provided, and the article situates SU6656 in a competitive landscape, bridging platelet biology and oncology.

• DOT1L Inhibition Enhances Lenalidomide Response in Myeloma

  2026-04-20

  The reference study demonstrates that DOT1L inhibition reprograms innate immune signaling to potentiate the anti-myeloma effects of lenalidomide (CC-5013). By dissecting the epigenetic and immune mechanisms, the research identifies new therapeutic avenues to overcome resistance and improve outcomes in multiple myeloma.

450 records 20/30 page Previous Next First page 上5页 1617181920 下5页 Last page